Skip to content

Screening for Masked Hypertension With Smart Wearable Devices (SMART)

Screening for Masked Hypertension in Young and Middle-aged Adults With Smart Wearable Devices (SMART)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05409898
Acronym
SMART
Enrollment
200
Registered
2022-06-08
Start date
2022-07-31
Completion date
2024-07-31
Last updated
2022-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Masked Hypertension

Keywords

asked hypertension, Smart wearable device

Brief summary

In recent years, a large number of consumer-grade and Smart Wearable Devices (SWD) such as smart watches, with BP measurement property, have entered the market and have a high configuration and utilization among young and middle-aged populations, but most of them are uncalibrated and have poor accuracy. Recently, several medical-grade smart BP watches have passed the national medical device registration test, which will provide an important tool for accurate screening of hypertension, especially masked hypertension, in young and middle-aged people. Screening for masked hypertension in young and middle-aged adults with smart wearable devices (SMART)aims to screen for masked hypertension using smart BP watches that have been tested for national medical device registration. It is planned to include 200 young and middle-aged subjects with normal blood pressure (BP) in the clinic, who will wear the smart BP watch for 7 consecutive days (BP will be measured at least once in the morning and once in the evening, 2-3 times each time), and if the mean BP is \>= 135/85 mmHg, it will be determined to be MK and recommended for further consultation and treatment.

Detailed description

Masked hypertension (MH) is defined as elevated ambulatory or home blood pressure (BP), but normal office BP, often complicated with severe cardiovascular and renal damage. MH is easily missed and needs to be identified by out-of-office BP measurements such as ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM). However, in clinical practice, ABPM has poor accessibility, high cost, and requires appointments, making it difficult to meet the demand; HBPM has better accessibility, but low utilization and irregular use are more prominent. In addition, these devices interfere with sleep and activity when measuring BP, so their clinical application is somewhat limited. Smart wearable devices (SWD) can sense and record various physiological parameters of human body, and analyze the health status of individuals with the support of software algorithms. In recent years, a large number of consumer-grade and SWD such as smart watches, with BP measurement property, have entered the market and have a high configuration and utilization among young and middle-aged populations, but most of them are uncalibrated and have poor accuracy. Recently, several medical-grade smart BP watches have passed the national medical device registration test, which will provide an important tool for accurate screening of hypertension, especially MH, in young and middle-aged people. Screening for masked hypertension in young and middle-aged adults with smart wearable devices (SMART) aims to screen for MH using smart BP watches that have been tested for national medical device registration. It is planned to include 200 young and middle-aged subjects with normal blood pressure in the clinic, who will wear the smart BP watch for 7 consecutive days (BP will be measured at least once in the morning and once in the evening, 2-3 times each time), and if the mean BP is \>= 135/85 mmHg, it will be determined to be MK and recommended for further consultation and treatment.

Interventions

DEVICEsmart wearable device

screening masked hypertension with smart wearable devices

Sponsors

HUAWEI
CollaboratorUNKNOWN
Jing Liu
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. 18-50 years of age, male or female 2. No clear previous history of hypertension and other cardiovascular diseases 3. Signed informed consent form

Exclusion criteria

1. Patients with established hypertension 2. History of severe heart, liver, or kidney disease 3. Inability to cooperate in completing the study

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of masked hypertension7 daysAverage systolic/diastolic BP during 7 days of the observation period will be calculated. Office BP should be measured when the average BP is ≥135/85 mmHg during 7 days of continuous self-monitoring. If the office BP is \< 140/90 mmHg at visit, Masked Hypertension will be diagnosed. The prevalence of masked hypertension will be calculated as the following: number of masked hypertension/number of subjects included.

Secondary

MeasureTime frameDescription
Prevalence of hypertension7 daysAverage systolic/diastolic BP during 7 days of the observation period will be calculated. Office BP should be measured when the average BP is ≥135/85 mmHg during 7 days of continuous self-monitoring. If the office BP is ≥140/90 mmHg at visit, the diagnosis will be Hypertension. The prevalence of hypertension will be calculated as the following: number of hypertension/number of subjects included.

Countries

China

Contacts

Primary ContactJing Liu, MD
heartcenter@163.com01088325457

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026